| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 4, 2006
Accepted on February 28, 2007
Department of Woman and Child Health, Divisions of Obstetrics and Gynecology and of Reproductive Endocrinology, and Department of Oncology-Pathology, Division of Pathology, Karolinska Institutet, Stockholm, Sweden
* To whom correspondence should be addressed. E-mail: hong.zang{at}ki.se.
Context: Available data concerning effects of testosterone on endometrium of postmenopausal women are seriously limited.
Objective: Our aim was to compare the influence of treatment with testosterone and/or estrogen on endometrial proliferation in healthy postmenopausal women.
Design: An open, randomized clinical study with parallel comparison of the groups.
Setting: Women's health clinical research unit and a research laboratory at a university hospital.
Participants: Sixty-three women who had experienced natural menopause.
Interventions: After random assignment, the participants were administered orally testosterone undecanoate (40 mg every second day), estradiol valerate (2 mg daily) or both for three months.
Main Outcome Measures: Endometrial thickness was measured and endometrial proliferation evaluated on the basis of histopathology and expression of Ki-67, a proliferation marker.
Results: Endometrial thickness was significantly increased by treatment with estrogen alone or in combination with testosterone but was unaltered by testosterone alone. Among the women receiving estrogen alone, the proportion exhibiting histopathology indicative of proliferation increased significantly to 50% (p <0.05), whereas there was a non-significant increase to 28% with the combined treatment and testosterone alone had no effect at all. Expression of Ki-67 was up-regulated significantly in both glands and stroma (p< 0.05 respectively) in both estrogen treatment groups. However, the expression was significantly higher in stroma by estrogen treatment alone than after combined treatment (p<0.05).
Conclusions: The short-term treatment with testosterone of postmenopausal women does not stimulate endometrial proliferation. In addition, testosterone appears to counteract endometrial proliferation induced by estrogen to a certain extent.
This article has been cited by other articles:
 |
|
 |
|
  S. R. Davis, M. Moreau, R. Kroll, C. Bouchard, N. Panay, M. Gass, G. D. Braunstein, A. L. Hirschberg, C. Rodenberg, S. Pack, et al. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen N. Engl. J. Med., November 6, 2008; 359(19): 2005 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mueller and L. Gooren Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones Eur. J. Endocrinol., September 1, 2008; 159(3): 197 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Otto, I. Fuchs, H. Altmann, M. Klewer, A. Walter, K. Prelle, R. Vonk, and K.-H. Fritzemeier Comparative Analysis of the Uterine and Mammary Gland Effects of Drospirenone and Medroxyprogesterone Acetate Endocrinology, August 1, 2008; 149(8): 3952 - 3959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Braunstein The Endocrine Society Clinical Practice Guideline and The North American Menopause Society Position Statement on Androgen Therapy in Women: Another One of Yogi's Forks J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4091 - 4093. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
